Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.02 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including oligodendrocytes; strongest in epididymal principal cells | 0.75 |
| chemistry Open Targets | reachable by antibody | 0.36 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 169 | 0.91 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 7381
Sealed predictions
- CELSR2 in dopamine neurons, braak-0.38 (p 0.315) → +0.41 (p 0.276)receipt 7390
- CELSR2 in oligodendrocytes, braak-0.32 (p 0.400) → -0.09 (p 0.820)receipt 7389
Swarm cases
receipt 7390: CELSR2 in dopamine neurons, braak
- power
- full sample -0.05 (p 0.840, n 18), 95% CI -0.51 to +0.43. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.09 (p 0.715, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.08 (p 0.761, n 18). could be the mix.
- skeptic
- leave-one-out range -0.20 to +0.01, sign flips 4; without severely affected donors -0.05 (p 0.840, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CELSR2 in dopamine neurons.
case closed: nothing better to follow up.
receipt 7389: CELSR2 in oligodendrocytes, braak
- power
- full sample -0.30 (p 0.228, n 18), 95% CI -0.67 to +0.20. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.30 (p 0.228, n 18). does not hold up.
- composition
- oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: -0.38 (p 0.123, n 18). could be the mix.
- skeptic
- leave-one-out range -0.45 to -0.22, sign flips 0; without severely affected donors -0.30 (p 0.228, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CELSR2 in oligodendrocytes.
case closed: nothing better to follow up.
Receipts
loading the receipts